TrialPloS one2018

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.

Nina Kimer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.